Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

816 related articles for article (PubMed ID: 11839685)

  • 1. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.
    Maulik G; Kijima T; Ma PC; Ghosh SK; Lin J; Shapiro GI; Schaefer E; Tibaldi E; Johnson BE; Salgia R
    Clin Cancer Res; 2002 Feb; 8(2):620-7. PubMed ID: 11839685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.
    Ma PC; Kijima T; Maulik G; Fox EA; Sattler M; Griffin JD; Johnson BE; Salgia R
    Cancer Res; 2003 Oct; 63(19):6272-81. PubMed ID: 14559814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activated c-Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer.
    Maulik G; Madhiwala P; Brooks S; Ma PC; Kijima T; Tibaldi EV; Schaefer E; Parmar K; Salgia R
    J Cell Mol Med; 2002; 6(4):539-53. PubMed ID: 12611639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells.
    Hov H; Holt RU; Rø TB; Fagerli UM; Hjorth-Hansen H; Baykov V; Christensen JG; Waage A; Sundan A; Børset M
    Clin Cancer Res; 2004 Oct; 10(19):6686-94. PubMed ID: 15475459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571.
    Wang WL; Healy ME; Sattler M; Verma S; Lin J; Maulik G; Stiles CD; Griffin JD; Johnson BE; Salgia R
    Oncogene; 2000 Jul; 19(31):3521-8. PubMed ID: 10918610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy.
    Li Y; Lal B; Kwon S; Fan X; Saldanha U; Reznik TE; Kuchner EB; Eberhart C; Laterra J; Abounader R
    Cancer Res; 2005 Oct; 65(20):9355-62. PubMed ID: 16230398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adaptor molecule Crk is required for sustained phosphorylation of Grb2-associated binder 1 and hepatocyte growth factor-induced cell motility of human synovial sarcoma cell lines.
    Watanabe T; Tsuda M; Makino Y; Ichihara S; Sawa H; Minami A; Mochizuki N; Nagashima K; Tanaka S
    Mol Cancer Res; 2006 Jul; 4(7):499-510. PubMed ID: 16849525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network.
    Webb CP; Hose CD; Koochekpour S; Jeffers M; Oskarsson M; Sausville E; Monks A; Vande Woude GF
    Cancer Res; 2000 Jan; 60(2):342-9. PubMed ID: 10667586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells.
    Song L; Turkson J; Karras JG; Jove R; Haura EB
    Oncogene; 2003 Jul; 22(27):4150-65. PubMed ID: 12833138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure, biosynthesis and biochemical properties of the HGF receptor in normal and malignant cells.
    Comoglio PM
    EXS; 1993; 65():131-65. PubMed ID: 8380735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
    Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
    Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of PI3K/Akt signaling pathway in hepatocyte growth factor-induced migration of uveal melanoma cells.
    Ye M; Hu D; Tu L; Zhou X; Lu F; Wen B; Wu W; Lin Y; Zhou Z; Qu J
    Invest Ophthalmol Vis Sci; 2008 Feb; 49(2):497-504. PubMed ID: 18234991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tyrosine phosphorylation of p145met mediated by EGFR and Src is required for serum-independent survival of human bladder carcinoma cells.
    Yamamoto N; Mammadova G; Song RX; Fukami Y; Sato K
    J Cell Sci; 2006 Nov; 119(Pt 22):4623-33. PubMed ID: 17062641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of the met receptor in mesothelioma.
    Mukohara T; Civiello G; Davis IJ; Taffaro ML; Christensen J; Fisher DE; Johnson BE; Jänne PA
    Clin Cancer Res; 2005 Nov; 11(22):8122-30. PubMed ID: 16299245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors.
    Burgess T; Coxon A; Meyer S; Sun J; Rex K; Tsuruda T; Chen Q; Ho SY; Li L; Kaufman S; McDorman K; Cattley RC; Sun J; Elliott G; Zhang K; Feng X; Jia XC; Green L; Radinsky R; Kendall R
    Cancer Res; 2006 Feb; 66(3):1721-9. PubMed ID: 16452232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autocrine and/or paracrine growth of aggressive ATLL cells caused by HGF and c-Met.
    Onimaru Y; Tsukasaki K; Murata K; Imaizumi Y; Choi YL; Hasegawa H; Sugahara K; Yamada Y; Hayashi T; Nakashima M; Taguchi T; Mano H; Kamihira S; Tomonaga M
    Int J Oncol; 2008 Oct; 33(4):697-703. PubMed ID: 18813782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increase in hepatocyte growth factor receptor tyrosine kinase activity in renal carcinoma cells is associated with increased motility partly through phosphoinositide 3-kinase activation.
    Nakamura T; Kanda S; Yamamoto K; Kohno T; Maeda K; Matsuyama T; Kanetake H
    Oncogene; 2001 Nov; 20(52):7610-23. PubMed ID: 11753639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion.
    Ma PC; Tretiakova MS; Nallasura V; Jagadeeswaran R; Husain AN; Salgia R
    Br J Cancer; 2007 Aug; 97(3):368-77. PubMed ID: 17667909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel recombinant soluble splice variant of Met is a potent antagonist of the hepatocyte growth factor/scatter factor-Met pathway.
    Tiran Z; Oren A; Hermesh C; Rotman G; Levine Z; Amitai H; Handelsman T; Beiman M; Chen A; Landesman-Milo D; Dassa L; Peres Y; Koifman C; Glezer S; Vidal-Finkelstein R; Bahat K; Pergam T; Israel C; Horev J; Tsarfaty I; Ayalon-Soffer M
    Clin Cancer Res; 2008 Jul; 14(14):4612-21. PubMed ID: 18628476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. beta-Catenin and actin reorganization in HGF/SF response of ST14A cells.
    Soldati C; Biagioni S; Poiana G; Augusti-Tocco G
    J Neurosci Res; 2008 Apr; 86(5):1044-52. PubMed ID: 17975841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.